Drug Approval | June 12, 2024
Glenmark receives ANDA approval for Esomeprazole Magnesium Delayed-Release capsules
Glenmark's current portfolio consists of 197 products authorized for distribution in the U.S. marketplace
Glenmark's current portfolio consists of 197 products authorized for distribution in the U.S. marketplace
his strategic collaboration with BluSim Tech marks a significant milestone in Fischer MVL's journey towards expanding its healthcare portfolio
ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset
According to IQVIATM sales data for the 12-month period ending March 2024, the Combigan Ophthalmic Solution, 0.2%|0.5% market achieved annual sales of approximately $290.0 million
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Glenmark’s Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg (OTC), will be distributed in the U.S. by Glenmark Therapeutics, USA
The exclusive agreement between AAHI and Croda includes a collaborative effort in research and development
Vericiguat works on a pathway not currently targeted by existing heart failure treatments
Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
Centhaquine is a resuscitative agent presently indicated for the treatment of hypovolemic shock by DGCI
Subscribe To Our Newsletter & Stay Updated
